US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Abliva AB

0.0280

0.0000

Volume:- -

Turnover:- -

Market Cap:45.14M

PE:-4.43

High:0.0280

Open:0.0280

Low:0.0280

Close:0.0280

52wk High:0.0374

52wk Low:0.0280

Shares:1.61B

Float Shares:873.79M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0063

EPS(LYR):-0.0060

ROE:-135.88%

ROA:-71.03%

PB:6.86

PE(LYR):-4.66

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Abliva AB

Exchange:

EXPERT

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.neurovive.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEVPF/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEVPF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEVPF\",,,,,undefined,":{"symbol":"NEVPF","market":"US","secType":"STK","nameCN":"Abliva AB","latestPrice":0.028,"timestamp":1765314000000,"preClose":0.028,"halted":0,"volume":0,"delay":15,"floatShares":873789550,"shares":1612000000,"eps":-0.006325,"marketStatus":"Closed","change":0,"latestTime":"12-09 16:00:00 EST Delay","open":0.028,"high":0.028,"low":0.028,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.006325,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765357200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.028,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEVPF\",,,,,undefined,":{"symbol":"NEVPF","floatShares":873789550,"roa":"-71.03%","roe":"-135.88%","lyrEps":-0.006015,"shares":1612000000,"dividePrice":0,"high":0.028,"amplitude":0,"preClose":0.028,"low":0.028,"week52Low":0.028,"pbRate":"6.86","psRate":"850.97","week52High":0.0374,"institutionHeld":0,"latestPrice":0.028,"eps":-0.006325,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.006325,"open":0.028,"prevYearClose":0.036,"prevWeekClose":0.028,"prevMonthClose":0.028,"prevQuarterClose":0.028,"fiveDayClose":0.028,"twentyDayClose":0.028,"sixtyDayClose":0.028},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEVPF\",params:#limit:5,,,undefined,":[{"date":"2024-05-23","symbol":"NEVPF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1716451200000,"name":null,"time":"","dateTimestamp":1716436800000,"actualEps":null},{"market":"US","date":"2024-02-23","symbol":"NEVPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1708664400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-17","symbol":"NEVPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1700197200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-18","symbol":"NEVPF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692345600000,"name":null,"time":"","dateTimestamp":1692331200000,"actualEps":null},{"date":"2022-08-19","symbol":"NEVPF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1660896000000,"name":null,"time":"","dateTimestamp":1660881600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEVPF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NEVPF\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.neurovive.com","stockEarnings":[{"period":"1week","weight":-0.3335},{"period":"1month","weight":-0.2389},{"period":"3month","weight":-0.1603},{"period":"6month","weight":-0.2128},{"period":"1year","weight":-0.7252},{"period":"ytd","weight":-0.2128}],"description":"Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.","exchange":"EXPERT","name":"Abliva AB","nameEN":"Abliva AB"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NEVPF\",market:\"US\",,,undefined,":null}}